Wells Fargo has increased its price target for HCA Healthcare by 22.8% to $468, while maintaining an Equal-Weight rating. This new target implies a slight downside of 1.1% from the stock's closing price on October 30, 2026, suggesting limited immediate upside according to this analyst.
Wells Fargo raised its price target on HCA Healthcare significantly, from $381 to $468, indicating a more optimistic valuation for the company. However, the firm maintained its 'Equal-Weight' rating, and the new target still implies a slight downside from the stock's current trading price. This suggests that while the analyst sees more value in HCA, they don't believe it's significantly undervalued or poised for a major upward move from its current level. For traders, this indicates a potentially neutral short-term outlook, with the long-term implications depending on whether HCA can exceed this new, higher target.